



# COVID-19: Air Travel, Public Health Measures and Risk

## A Brief Summary of Current Medical Evidence

IATA Medical Advisor / Medical Advisory Group

Version 4 – 10 June 2021

## Introduction / Purpose of the document

This summary is intended to provide the scientific foundation to assessing risk related to air travel during COVID-19. As the pandemic continues, and as vaccination programmes are under way in most countries, the considerations behind decisions regarding travel will continue to change. This document aims to provide an up to date evaluation of those considerations, based on available scientific evidence. It should be read with attention to the date of the latest revision, as the state of knowledge will continue to evolve rapidly.

It is prepared in the context of vaccination progress being at different stages in different countries. Despite the best efforts by WHO to aim for vaccine equity, countries are achieving vaccination at wildly different rates and it appears likely that this will continue to be the case. This means that the risk assessment around travel between one pair of countries may be very different from the assessment for another pair of countries.

## Part 1: Risk

### Risk Assessment Frameworks

- An assessment of risk needs to consider both likelihood and consequence. Risk cannot be avoided but the risk of a process can be balanced against the benefits, and against the risks of the counterfactual, to assist those who are tasked with making decisions. In particular the risks of international travel must be balanced against the risks of maintaining restrictions which include economic, employment, social and health risks. Part of the risk assessment process for a country will be determining how much risk, related to importing cases of COVID-19, can be accepted; this in turn may depend on the state of the public health system to detect (contact tracing, testing facilities) and manage (isolation and health care system) those cases.

### Flight-associated transmission

- Information on in-flight transmission is incomplete, but several published papers have examined instances of probable and possible flight-associated transmission. Documented instances are very

few [Bae, Chen J, Choi, Eichler, Eldin, Freedman, Hoehl, Khanh, Murphy, Nir-Paz, Pavli, Schwartz, Speake, Swadi, Thompson HA] compared with the total numbers of travellers, and while it must be assumed that these reports greatly underestimate the actual incidence, there appears sufficient evidence to conclude that this risk is low, particularly when masks are worn. The papers referred to describe instances of probable/suspected transmission associated with flight: some had little or no evidence of flight-related transmission compared with other origins [Eldin, Murphy, Schwartz] and most described flights with 1 or 2 presumed secondary cases in close proximity to the index case [Bae, Chen, Hoehl, Pavli]. In more recent studies the transmission was supported by whole genome sequencing [Choi, Eichler, Speake, Swadi].

- Since the start of the pandemic many protections have been added to commercial air travel aimed at preventing transmission [Khatib], and collectively have been referred to as the “Public Health Corridor” [ICAO]. One of the most obvious changes on-board is the implementation of mask wearing by passengers. There were few instances of suspected transmissions on flights when masks were worn by passengers [Nir-Paz, Swadi, Thompson, Eichler]. Universal wearing of face coverings appears to be an effective protection against spread via aerosols [Cheng]. Of all the presumed secondary cases in these published studies, half are from just two flights [Khanh, Speake], on which mask-wearing by passengers was not yet normal practice. This finding is in keeping with other studies showing that the majority spread originates from a small minority of cases [Yang Q]. The mechanism in those unusual cases with multiple secondaries is likely to be related to airborne carriage of fine aerosols [Chen, Davis, Fennelly, Klompas].
- In terms of risk the airline cabin compares favourably with other indoor environments [Hadei, Rivera-Rios] including restaurants [Lu], buses [Shen], churches [James, Kateralis], gymnasiums [Jang], and high-speed trains [Hu]. The mechanism presumed in such indoor environments is aerosol transmission [Allen, Kateralis]. There is even a well-documented transmission in a quarantine facility where the only contact between primary and secondary (linked by genome sequencing) was non-simultaneous opening of their room doors to the same corridor [Eichler], once again pointing to suspended aerosols. It has been suggested [Allen] that the characteristics of airline cabin air supply (rapid air flow, increased air changes, and HEPA filtration) should be applied to these other indoor environments.
- Returning to the aircraft environment, although some earlier studies (pre-COVID) pointed to the possibility of spread particularly across rows [Chen, Olsen, Wang Z, Wilder-Smith], supporting evidence for low transmission risk in flights comes from modelling with computational fluid dynamics [Davis, Davis, Pang] and a large experimental study using actual aircraft cabins [Kinahan]. A recent modelling study reinforces the gradient of risk with distance from source, suggesting lower relative risk with the “empty middle seat” [Dietrich] but does not account for mask wear, and conflicts with the more complex analysis above [Davis]. Finally, note that other factors may be relevant, and of particular note is that speech, particularly loud speech, may be an underestimated determinant of aerosol transmission [Andersson], and one which could be relevant to the apparent low risk of on-board spread.
- Travel encompasses an entire journey including not only aircraft but also surface transport (road/rail etc) and airports. Any discussion of air travel, or of its risk, needs to have all of those elements considered. In some of the studies above, it is not clear at what part of the journey transmission may have occurred.
- Most of the studies referred to above were undertaken prior to the appearance of more transmissible variants, which are discussed in part 3 of this report. In the absence of evidence to the contrary, it must be assumed that flight-related transmission of variants would be increased proportionately.
- Even if transmission during travel was completely eliminated, the much more challenging problem to solve is the risk of importation of cases which are incubating at the time of travel [Pana]. The main focus of this document is on importation risk. This is the risk to be weighed by countries in seeking to

allow increased international travel, one which in many countries is managed with mandatory quarantine after arrival [Kiang].

- The surface route of transmission has been assessed as low when compared with droplet and aerosol routes – and dealt with by standard cleaning and disinfection practices. A US CDC report [CDC] suggested that “the risk of fomite transmission can be reduced by wearing masks consistently and correctly, practicing hand hygiene, cleaning, and taking other measures to maintain healthy facilities.”

## Part 2: Vaccinations and immunity – effect on risk

### Impact of vaccines on severe disease/mortality, and transmission

- There is abundant evidence from clinical trials and real-world data that vaccination reliably prevents severe disease, hospitalisation, and death [Dagan, Pawlowski, Tenforde, Vahidy, Vasilieou] – even in the small minority who become infected after vaccination [Bernal]. What is less clear is the degree to which vaccination can prevent mild or asymptomatic infection – the likely pathway being that viral colonisation of the upper respiratory tract could result in shedding of virus before the immune response has fully been triggered and effected. Even in the scenario of a strong vaccine-mediated immune response, the possibility remains that a proportion mild or asymptomatic cases may not be prevented [Bleier]. Therefore, since asymptomatic transmission is an important contributor to transmission [Johansson, Letizia, Oran, Rasmussen, Ren], it is necessary to determine the extent to which vaccination will reduce transmission.
- A number of recent studies provide results which suggest that vaccination also prevents infections of all severity, including asymptomatic [Amit, Bernal, Chodick, Dagan, Daniel, Menni]. Some specifically demonstrate reduction in asymptomatic infection [Angel, Haas, Jones, Lillie, Lumley, Milman, Pritchard, Sadoff, Shah, Tande, Weekes], in most cases by a large percentage. Others demonstrate that onward transmission is largely reduced, looking at data on transmission within families [Harris, Salo, Shah], within residential care communities [Cavanaugh, De Salazar, Monge] or amongst regularly screened employees [Keehner, Swift, Tang].
- An alternative approach is to model the predicted transmission from general efficacy trials [Lipsitch], also suggesting transmission is low in those vaccinated. Another is to look at viral load, which correlates with infectiousness [Marc, Marks]. There is animal evidence that vaccination leads to reduced viral load in the unvaccinated population, and human evidence that those who become infected post-vaccination have reduced viral load [Levine-Tiefenbrun, McEllistrem]. Note that immune response may vary with age [Moustsen-Helms, Müller, Yang HS]. Antibodies detected in the upper respiratory tracts of vaccinated people, both IgA and IgG [Becker, Madés, Sterlin] suggest a mechanism for reduced transmission.
- Taken together, these findings point to significant reduction in transmission by those who have been fully vaccinated [Richterman]. The question of duration of immunity and the effect of variants are both discussed below. Some vaccines may perform better than others, and this is likely to be a factor considered by countries in permitting international travel. One group that shows reduced immune response from vaccination is the immunosuppressed, particularly solid organ transplant recipients [Boyarsky].
- Most of these studies show that the vaccines prevent asymptomatic transmission somewhat less efficiently than symptomatic, therefore it is likely that a high proportion of those “breakthrough” cases occur in a vaccinated community will be asymptomatic [Gruskay, White]. This observation may prompt

consideration of some surveillance testing of vaccinated travellers in communities with a low tolerance for introduced cases – even though they will have reduced chance of onward transmission.

## Duration of immunity following vaccination or infection

- Several studies point to immunity being retained beyond 6 months following vaccination [Doria-Rose, Pegu] and data on this will accumulate. Immunity is complex, and laboratory studies looking only at antibody production do not tell the full story of immunity which involves cellular and local responses as well. Cell-mediated immunity may be maintained even with declining antibody levels [Tarke]. Studies have been conducted to evaluate booster doses [Wu], and delayed second dose [Abu-Raddad]. Using a different vaccine for the second dose from the first, known as “heterologous prime-boost,” has shown strong or enhanced antibody response [Frias, Groß]. Immunity following vaccination has been demonstrated in pregnant and lactating women [Collier].
- There are still questions about the strength and duration of immunity of those who have had documented infections with COVID-19, but evidence is accumulating to suggest good immunity for several months [Dan, Krutikov] and even beyond a year [Gallais]. Protection appears to be less in older people [Hansen]. There are cases of individuals with proven second infections (with genetically different virus) including some more severe cases in the second infection, but they remain rare [Piri, Tillett, Vitale] with a rate around 0.7% [Qureshi] and a tendency to less severe infections the second time. They are more common in older [Wall] and immunosuppressed [Agha] people. It is yet to be established whether second infection is more common with some of the variants. Recovery from infection followed by a booster vaccination has been shown to produce strong antibody response [Gallais]. Finally, there is evidence that recovery from COVID-19 infection is associated with good immunity against variants [Hall, Redd].

## Vaccine safety concerns

- Early in 2021, cases were observed of a rare type of blood clotting disorder (under various names including thrombosis and thrombocytopenia syndrome TTS), some severe or fatal, in the days after receiving the AstraZeneca vaccine [Greinacher, Schultz]. Initially these were considered not elevated above population rates, but subsequently they were classified as rare side effects of vaccination for the AstraZeneca vaccine [See, Schultz]. The benefit was assessed as outweighing risk in the older age groups, but many countries suspended use of some vaccines in younger age groups (using a variety of age cut-offs) and some suspended use altogether [Karron]. Investigations continue into whether there is a causal relationship with vaccination, such as by induction of antibodies to clotting pathway mediators [Cines]. Although some cases were also reported in association with the Johnson & Johnson vaccine, they were at lower rates [Sadoff] and this vaccine was later cleared by major regulators for resumption of use. A meta-analysis [Chan] of data from 10 countries points out the low incidence in the elderly, with a clear overall benefit of vaccine, with a higher risk in the younger adults where the risk-benefit ratio may depend on local COVID prevalence. A newer South African study [Takuva] showed low rates of these complications.
- A separate concern was raised more recently regarding myocarditis following second doses of the Pfizer vaccine, particularly in younger males, and this remains under investigation.

## Part 3: Virus variants – effect on risk

### Impact on transmission

- The appearance and proliferation of more transmissible variants of the SARS-CoV2 virus since late 2020 have changed the risk equations somewhat. A higher  $R_0$  (reproduction number) is how this is

considered in risk modelling. Currently the Alpha/B.1.1.7 (first identified in UK), Beta/B.1.351 (South Africa) Gamma/P1 (Brazil) and Delta/B.1.617.2 (India) are the dominant variants, and there is well-established evidence of greater transmissibility in all [Faria, Faria, Horby, Mascola, Munitz, Tegally, Wall]. In Israel the B.1.1.7 variant became the dominant strain in under a month, being significantly more transmissible [Munitz]. The more the SARS-CoV-2 virus continues to proliferate, the more likely it is that more transmissible variants will appear and eventually predominate.

## Impact on severity

- There has been preliminary evidence that variants have slightly greater propensity to cause severe illness than the original “wild” virus – in particular, in the case of the B.1.351 and possibly the P1. Although there were preliminary indications of greater mortality for the B.1.1.7 variant [Davies], other studies have not borne this out [Frampton, Graham]. The B.1.1.7 variant appears to lead to a longer period of infectiousness [Kissler], which may contribute to its increased transmissibility.

## Impact on testing effectiveness

- Studies to date seem to agree that PCR tests remain sensitive to the currently circulating variants of concern, but some antigen tests which target single spike protein sites could be of reduced efficacy against some or all of those variants with spike protein differences. Some caution should be applied before implementing any antigen tests at scale, to verify their effectiveness with variants of concern in circulation.

## Impact on vaccine effectiveness

- The evidence suggests that there may be some decline in effectiveness of some vaccines against currently circulating variants of concern [Emery, Ho, Ikegame, Kustin, Mascola, Wang P], and studies point to the greatest impact so far being in the case of the AstraZeneca vaccine having limited effectiveness against the B.1.351 variant [Madhi, Wang P]. Most approved vaccines appear effective in preventing severe disease, hospitalisation and death [Rubin]. Furthermore, available evidence suggests that the mRNA vaccines in wide distribution (Pfizer-BioNTech and Moderna) appear to retain reasonably strong effectiveness overall against the current variants [Abu-Raddad, Benenson, Keehner, Kustin, Liu, Tarke, Thompson MG, Wu]. Neutralizing antibodies appear have been shown to be produced against a range of variants [Edara]. Another study showed efficacy in pregnant and lactating women [Collier]. New vaccine formulations are being tested to improve efficacy against variants.
- A South African study [Shinde] confirmed around 60% efficacy of the Novavax vaccine against the B.1.351 variant (but 49% in the HIV positive participants). The Pfizer vaccine demonstrated in vitro activity against the B.1.351 and B.1.1.7 variants as well as the variants identified in New York (B.1.526) and California (B.1.429) classified in USA as variants of concern [Liu], and activity was confirmed beyond 6 months [Pegu]. A study from Public Health England showed effectiveness after two doses of either AstraZeneca or Pfizer [Bernal2], and there are indications of likely activity of vaccine-induced antibodies against the B.1.617 subgroups and B.1.618 [Tada]. Some studies, however indicated some reduced activity of the Pfizer vaccine against the B.1.617 variants [Hoffman, Vaidyanathan], and of reduced activity specifically against B.1.617.2/Delta [Wall] particularly after only one dose [Bernal2].

## Part 4: Reducing the risk with international travel

### Quarantine of travellers

- Quarantine is applied differently in different locations. It ranges from total confinement in a locked guarded hotel room through to instruction to remain home but relying on an “honesty system” – the latter having been shown to have non-compliance rates up to 80% in studies. At the stringent end of the spectrum it is substantially (but not completely) effective at preventing importation of cases, whereas at the lax end of the spectrum it may provide only modest reduction of risk [Oxera]. As discussed above, testing programmes can enhance quarantine and may be able to allow reduction of the duration or stringency of quarantine measures, without significantly increasing importation risk [Johansson, Russell]. IATA has determined from repeated customer surveys, and observed travel patterns that quarantine requirements are a major disincentive to travel [IATA internal].

### Testing technologies and strategies

- While PCR has remained the primary diagnostic test throughout the pandemic, there has been increasing development of rapid antigen tests (RAT). Initially these were of much lower cost and higher speed than PCR testing, but of reduced sensitivity and specificity. Progressively through the pandemic these differences have reduced, with the cost and time of PCR testing reducing, and the sensitivity (and specificity) of RAT improving. Now there are some extremely rapid PCR tests and some studies show RAT tests with very good sensitivity and specificity [Pilarowski, Pekosz] although this is not a consistent finding [Dinnes]. In some situations, RAT testing may have an advantage over PCR in detecting only the cases most likely to be infectious [Norizuki, Pekosz]. However, the sensitivity of RAT testing appears to be less when used in asymptomatic people [Dinnes, Nkemakonam, Pollock], or when viral load is low [Muhi, Oh] This is important in the context of testing travellers, since asymptomatic cases are a large contributor to transmission [Johansson, Letizia, Oran, Ren]. This area continues to evolve rapidly [Humphries] and a further Cochrane review of RAT performance is awaited [Dinnes].
- A further relevant consideration is acceptability. Importantly saliva-based testing which has been validated extensively for PCR but not for RAT, can be applied frequently with high effectiveness [Babady, Norizuki, Tan, Wyllie] and much less drop-out than nasopharyngeal or oronasal swabbing [Ehrenberg]. Although reported results have been varied, the effectiveness depends on having clarity of the method used; salivary PCR has the potential to become the gold standard [Tan]. A further development is the use of anterior nasal self-sampling, shown to be sensitive to medium to high viral loads [Osmanodja], and such a method is now accepted by US CDC if done with an approved test, in conjunction with a telehealth provider affiliated with the test manufacturer, and with identity verified and documented.
- Effectiveness needs to be considered in the real world, which means consideration of implementation, delivery, reliability (across different users), acceptability and scalability. Turnaround time is also important – if a more accurate test takes 1-2 days to get a result, this may be less effective than a less sensitive test with an immediate result (to allow earlier intervention such as isolation). It is more appropriate to consider not just a test, but the effectiveness of a test strategy (for example, weekly PCR testing for a group of workers, vs RAT every day or every second day) [Holmdahl, Larremore, Mina, Mina]. Conversely, routine one-off testing of low prevalence populations does have a high risk of missed cases (due to reduced sensitivity in asymptomatic people) as well as false positives (due to the Bayesian effect of amplifying their likelihood in a low prevalence group). Routine RAT testing would need to have a means of conducting confirmatory (probably PCR) testing as rapidly as possible. Such a system was examined in Japanese travellers, using salivary antigen tests as the primary with PCR confirmation when required [Yokota] but limited sensitivity may still be a concern and further analysis is

awaited. In a different setting, a randomised controlled trial of attending an indoor event included demonstration of the possible utility of an antigen test pre-entry [Revollo].

- There are other molecular tests as alternatives to PCR, including isothermal PCR or “LAMP” which use alternative amplification methods, usually achieving greater speed of testing. There are also quantitative antigen tests which may have improved acceptability in certain domains. This is a rapidly changing field. Other novel technologies such as breath spectroscopy [Rusciewicz] and detector dogs [Grandjean] show potential. These should be considered, although both efficacy and scalability are yet to be established.

## Reduction in importation risk from testing

- The first requirement may be for the country of destination to set the level of risk of importation that it can accept, taking into account the epidemiological situation, the capacity of the health system to manage cases, and the capacity and reliability of the contact tracing system locally [Steyn].
- A number of studies have modelled the possible reduction in importation risk from testing in association with international travel [Clifford, Dickens, Goel, Johansson, Kiang, Russell, Smith, Steyn, Wells]. A Cochrane review of 62 studies [Burns] noted that most of the studies are from modelling only, with few real-world examples, but it only covered publications up to November 2020 and a further review is awaited. WHO [personal communication] also undertook a detailed analysis but only of papers up to November 2020. Several further papers have subsequently been published [Dickens, Johansson].
- In situations where travel is from low prevalence to high prevalence, the importation risk is low with a negligible incremental case likelihood. Modelling has indicated that destinations already with a high new case rate receive minimal impact from imported cases [Russell].
- With travel between countries of similar new case rates at the time of travel (provided that the rate data is reliable, with adequate testing programmes in place) then testing around the time of travel will reduce importation by a significant proportion [Clifford, Johansson, Oxera]. This should ensure that the travellers entering are of lower risk than the community at the destination and protect significantly against introducing a variant not already present.
- Efficacy of testing to reduce importation is better if closer to the time of travel; testing on arrival is still more effective. However in-airport testing creates logistical challenges at large scale.
- Travel from high prevalence to low prevalence locations presents more challenges, and in most cases, such travel currently requires some form of quarantine. There is consensus from modelling studies that a programme of testing in association of travel can be applied which will reduce the required quarantine, if not eliminating it entirely [Goel, Johansson, Kiang, Quilty, Russell, Smith, Wells]. Many seem to converge on a short period of quarantine (3-7 days) with testing at the start and end [Humphries, Johansson].
- As noted above, no pre-flight testing system can fully prevent travellers from having already been infected, and incubating at the time of travel. The timing of testing in relation to travel has been studied, and many countries have introduced a requirement for testing in the 72 hours prior to travel. This strikes a compromise between the risk of becoming infected in the time between the test and the travel, and the difficulties of reliably obtaining and confirming a result prior to travel. Testing 48-72 hours prior to travel has been assessed by different studies as reducing the importation risk but to varying degrees [Clifford, Johansson, Oxera].



- Testing in association with quarantine has been studied, and many indicate that a quarantine period of around 7 days, with 2 or 3 occasions of PCR testing (or in some cases RAT testing) can be as effective as a 14 day quarantine period, at reducing importation risk [Dickens, Johansson].
- If the destination is prepared to accept a higher risk of imported cases, based on its public health systems (including contact tracing), then even shorter periods, supported by testing programmes, could be acceptable. [Clifford, Goel, Johansson, Kiang, Russell, Smith, Wells]. If the risk is further reduced by travellers being vaccinated, along with validated testing programmes, the need for quarantine may be able to be removed, if based on sound studies.

## Contact tracing

- Regardless of the state of vaccination, the systems and processes of contact tracing remain vital in blocking chains of transmission and preventing spread. As countries begin to achieve control of the epidemic, contact tracing becomes even more vital for maintaining that control [Lash]. Systems which facilitate tracking and tracing (such as applications which record places visited, with or without GPS tracking assistance or detection of other visitors in the vicinity) are part of the risk management process. For example, some countries allow exit from quarantine on condition of using a GPS tracking device for a period of days. Applications that release location data have obstacles to widespread acceptance by users although some have addressed this by ensuring users retain control over the release of information [O'Connell]. For both public health authorities and airlines, an important element of managing the risks of air travel is the use of a passenger locator form, ideally an electronic one, to assist with follow-up of any passengers later found to be a positive case, and potentially infectious during travel. The ability of a destination to carry out contact tracing on arriving travellers is an important component of assessing travel-related risk.

## Part 5: Differing national approaches

- Current approaches of countries are highly divergent. At mid-April 2021, a little under half of countries required tests for arriving travellers, and around 80 countries required quarantine. Of those requiring tests, two-thirds required PCR testing, and a third required more than one test for each traveller. About 15 countries allow quarantine to be shortened on the basis of tests. Eight countries were exempting vaccinated travellers from quarantine [WHO, personal communication], most requiring the travel to be at least 2 weeks following vaccination.
- Any of these approaches depend on being able to verify that the required testing or vaccination has been carried out, and verify the identity of the traveller as matching the person whose result is presented. IATA has developed its travel pass for exactly this purpose, and there are also some other applications which fulfil similar functions; such electronic solutions will be necessary to support scaled-up numbers of travellers and many countries are already using them on a trial basis.

## Part 6: Other relevant considerations

### Therapeutics

- Little of the focus of this document has been on therapeutics. But if treatments become available which reliably and affordably prevent infection from progressing to becoming severe and fatal, the risk equations will be dramatically altered. This aspect needs to be considered, but at this stage, whilst there have been many gains from various therapies (including steroids, anti-thrombotics, antivirals, anti-inflammatories, interferon, various monoclonal antibodies, etc) the available therapeutics appear



so far to have made relatively little global impact on the infection fatality ratio. A meta-analysis of the monoclonal antibody agent tocilizumab [Avni] looking at eight randomised controlled trials showed reduction in 28-day mortality, requirement for ventilation and ICU admission.

- There also needs to be consideration of the more severe and prolonged complications of mild to moderate cases [Nasserie], increasingly referred to as “long COVID” and carrying significant health, social and economic effects [Mallapaty]. If therapies were developed and broadly available that reduced mortality and morbidity to a level commensurate with influenza, travel restrictions would likely not be justified.
- There will also be other advances; for example, a sulfate polysaccharide nasal spray was shown in an initial randomised controlled trial in Argentina to prevent a high proportion of cases in health care workers [Figueroa], and a further nasal spray of nitric oxide being explored.

## Part 7: References

Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* [Letter] 2021, May 5. DOI: 10.1056/NEJMc2104974  
Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2104974>

Abu-Raddad LJ, Chemaitelly H, Yassine HM, et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses, *Journal of Travel Medicine*, 2021;, taab083, <https://doi.org/10.1093/jtm/taab083>

Agha M, Blake M, Chilleo C, et al. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv [Pre-print] [Posted 2021, Jun 4].  
doi: <https://doi.org/10.1101/2021.04.06.21254949>

Allen JG, and Ibrahim AM. Indoor air changes and potential implications for SARS-CoV-2 transmission. *JAMA*. Published online April 16, 2021. doi: 10.1001/jama.2021.5053. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2779062>

Amit S, Regev-Yochay G, Afek A, et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. 2021, Mar 6. *Lancet* 397(10277):875-7 Published on line 2021, Feb 18. Doi: [https://doi.org/10.1016/S0140-6736\(21\)00448-7](https://doi.org/10.1016/S0140-6736(21)00448-7)

Andersson J. What drives transmission of severe acute respiratory syndrome coronavirus 2? *J Intern Med* [Editorial] [On-line 2021, May 28]. DOI: <https://doi.org/10.1111/joim.13335>

Angel Y, Spitzer A, Henig O, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. *JAMA*. Published online May 6, 2021. doi:10.1001/jama.2021.7152 Available from: <https://jamanetwork.com/journals/jama/fullarticle/2779853>

Avni T, Leibovic L, Cohen I, et al. Tocilizumab in the treatment of COVID-19 - a meta-analysis. *QJM: An International Journal of Medicine*, hcab142, <https://doi.org/10.1093/qjmed/hcab142>



Babady NE, McMillen, Jani K, et al. Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples. *The Journal of Molecular Diagnostics*, Volume 23, Issue 1, 3 – 9. Available from: [https://www.jmdjournal.org/article/S1525-1578\(20\)30541-9/fulltext](https://www.jmdjournal.org/article/S1525-1578(20)30541-9/fulltext)

Bae SH, Shin H, Koo HY, Lee SW, Yang JM, Yon DK. Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight. *Emerg Infect Dis*. 2020 Aug 21;26(11). doi: 10.3201/eid2611.203353. Epub ahead of print. PMID: 32822289. Available from: [https://wwwnc.cdc.gov/eid/article/26/11/20-3353\\_article](https://wwwnc.cdc.gov/eid/article/26/11/20-3353_article)

Bailey RI, Cheng HH, Chase-Topping M, et al. Pathogen transmission from vaccinated hosts can cause dose-dependent reduction in virulence. *PLOS Biology*. Published: March 5, 2020. <https://doi.org/10.1371/journal.pbio.3000619>

Becker M, Dulovic A, Junker D, et al. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals medRxiv [Preprint] [Posted 2021, Mar 10]. doi: <https://doi.org/10.1101/2021.03.08.21252958>

Benenson S, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers. Pre-print Mar 2021. DOI: 10.1056/NEJMc2101951. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2101951>

Bleier BS, Ramanathan M, Lane A. COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission. *Otolaryngology– Head and Neck Surgery* 2021, Vol. 164(2) 305–307 DOI: 10.1177/0194599820982633. Available from: <https://journals.sagepub.com/doi/10.1177/0194599820982633>

Bernal JL, Andrews N, Gower C, et al. Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. medRxiv [Preprint] [Posted 2021, May 18] doi: <https://doi.org/10.1101/2021.05.14.21257218>

Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv [Pre-print][Posted 2021, May 24] doi: <https://doi.org/10.1101/2021.05.22.21257658>

Bernal JL, Gower C, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 2021; 373 (Published 13 May 2021). doi: <https://doi.org/10.1136/bmj.n1088>

Bertollini R, Chemaitelly H, Yassine HM, et al. Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. *JAMA*. Published online June 09, 2021. doi:10.1001/jama.2021.9970. Available from: <https://jamanetwork.com/journals/jama/article-abstract/2781112>

Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA*. 2021;325(21):2204–2206. doi:10.1001/jama.2021.7489. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2779852>

Burns J, Movsisyan A, Stratil JM, et al. International travel-related control measures to contain the COVID-19 pandemic: a rapid review. *Cochrane Database Syst Rev*. 2021 Mar 25;3:CD013717. doi: 10.1002/14651858.CD013717.pub2.PMID: 33763851. Available from: <https://pubmed.ncbi.nlm.nih.gov/33763851/>

Cavanaugh AM, Fortier S, Lewis P, et al. COVID-19 outbreak associated with a SARS-CoV-2 R.1 lineage variant in a skilled nursing facility after vaccination program — Kentucky, March 2021. *MMWR Morb Mortal Wkly Rev* 70(17):639–643. 2021, Apr 30. <https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e2.htm>

CDC. US Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 and Surface (Fomite)



Transmission for Indoor Community Environments. Posted 2021, Apr 5. Available from:  
<https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surface-transmission.html>

CDC US Centers for Disease Control and Prevention. COVID-19 vaccine breakthrough infections reported to CDC – United States, January 1 – April 30, 2021. MMWR Morb Mortal Wkly Rep. ePub: 25 May 2021. DOI:  
<http://dx.doi.org/10.15585/mmwr.mm7021e3>.

Chan BTB, Bobos P, Odutayo A, et al. Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine. medRxiv [Pre-print] [Posted 2021, May 8] doi: : <https://doi.org/10.1101/2021.05.04.21256613>

Chen J, He H, Cheng W, Liu Y, Sun Z, Chai C, Kong Q, Sun W, Zhang J, Guo S, Shi X, Wang J, Chen E, Chen Z. Potential transmission of SARS-CoV-2 on a flight from Singapore to Hangzhou, China: An epidemiological investigation. Travel Med Infect Dis. 2020 Jul-Aug;36:101816. doi: 10.1016/j.tmaid.2020.101816. Epub 2020 Jul 6. PMID: 32645477; PMCID: PMC7336905. Available from:  
<https://www.sciencedirect.com/science/article/abs/pii/S1477893920303124>

Chen PZ, Bobrovitz N, Premji Z, et al. Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols. MedRxiv [Preprint]. [Posted 2020 Oct 15]. Available from:  
<https://www.medrxiv.org/content/10.1101/2020.10.13.20212233v1>

Chen Q, McDevitt JJ, Gupta JK, Jones BW, Mazumdar S, Poussou SB, Spengler JD (National Air Transportation Center of Excellence for Research in the Intermodal Transport Environment (RITE); Airliner Cabin Environment Research Program, Harvard School of Public Health; Kansas State University; and Purdue University). U.S

Cheng Y, Witt C, Rapp S, et al. Face masks effectively limit the probability of SARS-CoV-2 transmission. Science [Published on line 2021, May 20] doi: 10.1126/science.abg6296. Available from:  
<https://science.sciencemag.org/content/early/2021/05/19/science.abg6296>

Chodick G, Tene L, Patalon T, et al. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. JAMA Netw Open. 2021 Jun 1;4(6):e2115985. doi: 10.1001/jamanetworkopen.2021.15985. PMID: 34097044. Available from:  
<https://pubmed.ncbi.nlm.nih.gov/34097044/>

Choi EM, Chu DKW, Cheng PKC, Tsang DNC, Peiris M, Bausch DG, Poon LLM, Watson-Jones D. In-Flight Transmission of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020 Sep 18;26(11). doi: 10.3201/eid2611.203254. Epub ahead of print. PMID: 32946370. Available from:  
[https://wwwnc.cdc.gov/eid/article/26/11/20-3254\\_article](https://wwwnc.cdc.gov/eid/article/26/11/20-3254_article)

Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia JAMA, 2021, Apr 16 [Editorial]. DOI: 10.1056/NEJMe2106315. Available from:  
<https://www.nejm.org/doi/full/10.1056/NEJMe2106315?query=TOC>

Clifford S, Quilty BJ, Russell TW, Liu Y, Chan YWD, Pearson CAB, Eggo RM, Endo A, CMMID COVID-19 Working Group, Flasche S, Edmunds WJ. Strategies to reduce the risk of SARS-CoV-2 re-introduction from international travelers. MedRxiv [Preprint]. [Posted 2020 Jul 25]. Available from:  
<https://www.medrxiv.org/content/10.1101/2020.07.24.20161281v2>

Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. Published online May 13, 2021. doi:10.1001/jama.2021.7563. Available from:  
<https://jamanetwork.com/journals/jama/fullarticle/2780202>



Corchado-Garcia J, Puyraimond-Zemmour D, Hughes T, et al. Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19. medRxiv [Pre-print] [2021, Apr 30].

Doi: <https://doi.org/10.1101/2021.04.27.21256193>

Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide vaccination setting. N Engl J Med. (Pre-print) February 24, 2021. DOI: 10.1056/NEJMoa2101765. Available from:

<https://www.nejm.org/doi/full/10.1056/NEJMoa2101765?query=TOC>

Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371(6529):eabf4063. Available from:

<https://science.sciencemag.org/content/371/6529/eabf4063>

Daniel W, Nivet M, Warner J, et al. Early evidence of the effect of SARS-CoV-2 vaccine and one medical center. N Engl J Med 2021 Mar. Preprint.

Available from: <https://www.nejm.org/doi/10.1056/NEJMc2102153>

Davies NG, Jarvis CI, CMMID COVID-19 Working Group, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature (2021). <https://doi.org/10.1038/s41586-021-03426-1>

Davis AC, Menard DJ, Clark AD, et al. Comparison of cough particle exposure for indoor commercial and aircraft cabin spaces. medRxiv [Pre-print] [Posted 2021, Mar 26]. Available from:

<https://doi.org/10.1101/2021.03.24.21254275>

Davis AC, Zee M, Clark AD. Computational fluid dynamics modelling of cough transport in an aircraft cabin. bioRxiv [Preprint]. [Posted 2021, Feb 17] Available from:

<https://www.biorxiv.org/content/10.1101/2021.02.15.431324v1>

De Salazar PM, Link N, Lamarca K, et al. High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities. medRxiv [Preprint] [Posted 2021, Apr 13]

doi: <https://doi.org/10.1101/2021.04.08.21255108>

Dickens BL, Koo JR, Lim JT, et al. Strategies at points of entry to reduce importation risk of COVID-19 cases and reopen travel. J Travel Med 2020. taaa141. Available from: <https://pubmed.ncbi.nlm.nih.gov/32841354/>

Dietrich WL, Bennett JS, Jones BW, et al. Laboratory Modeling of SARS-CoV-2 Exposure Reduction Through Physically Distanced Seating in Aircraft Cabins Using Bacteriophage Aerosol — November 2020. US HHS CDC Morbidity and Mortality Weekly Report, Early Release / Vol. 70 April 14, 2021. Available from: [Morbidity and Mortality Weekly Report \(MMWR\) | MMWR \(cdc.gov\)](https://www.cdc.gov/mmwr/mmwr-reports/2021/s41.html)

Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No.: CD013705. DOI:

10.1002 / 14651858.CD013705. Available from:

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013705.pub2/full>

Doria-Rose N, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med 2021 Apr. Preprint DOI: 10.1056/NEJMc2103916. Available from:

<https://www.nejm.org/doi/full/10.1056/NEJMc2103916>

Edara V, Lai V, Sahoo MK, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv [preprint] [Posted 2021, May 10] doi:

<https://doi.org/10.1101/2021.05.09.443299>



Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. *JAMA*. 2021;325(18):1896–1898. doi:10.1001/jama.2021.4388. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2777898>

Ehrenberg AJ, Moehle EA, Brook CE, et al. Launching a saliva-based SARS-CoV-2 surveillance testing program on a university campus. *medRxiv [Pre-print]* [2021 Jan 30]. doi: <https://doi.org/10.1101/2021.01.24.21250385>

Eichler E, Thornley C, Swadi T, et al. Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 during Border Quarantine and Air Travel, New Zealand (Aotearoa). *Emerg Inf Dis* May 2021. 27(5). Available from: [https://wwwnc.cdc.gov/eid/article/27/5/21-0514\\_article](https://wwwnc.cdc.gov/eid/article/27/5/21-0514_article)

Eldin C, Lagier JC, Mailhe M, Gautret P. Probable aircraft transmission of Covid-19 in-flight from the Central African Republic to France. *Travel Med Infect Dis*. 2020 May-Jun;35:101643. doi: 10.1016/j.tmaid.2020.101643. Epub 2020 Apr 1. PMID: 32247016; PMCID: PMC7194574. Available from: <https://doi.org/10.1016/j.tmaid.2020.101643>

Emary KRW, Golubchik T, Parvinder KA, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). *Lancet (Pre-print)* 2021, Feb. Available from: [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3779160](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160)

Faria NR, Claro IM, Candido D, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. *Genom Epidemiol*. 2021 Jan (Preprint). Available from: <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586>

Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* 14 Apr 2021: eabh2644. DOI: 10.1126/science.abh2644. Available from: Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. *Lancet Respir Med*. 2020;8:914-924. Available from: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30323-4/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30323-4/fulltext)

Federal Aviation Administration, Office of Aerospace Medicine; 2012 Feb. Infectious Disease Transmission in Airliner Cabins. Report No. RITE-ACER-CoE-2012-01. Contract No.: 07-C-RITE and 10-C-RITE. Available from: [https://www.faa.gov/data\\_research/research/med\\_humanfacs/cer/media/InfectiousDiseaseTransmission.pdf](https://www.faa.gov/data_research/research/med_humanfacs/cer/media/InfectiousDiseaseTransmission.pdf)

Figueroa JM, Lombardo M, Dogliotti A. Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02). *medRxiv [Pre-print]* [Posted 2021, Apr 15]. Available from: : <https://doi.org/10.1101/2021.04.13.21255409>

Frampton D, Rampling T, Cross A, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. *Lancet (Pre-print)* 2021, April. DOI:[https://doi.org/10.1016/S1473-3099\(21\)00170-5](https://doi.org/10.1016/S1473-3099(21)00170-5). Available from: <https://www.thelancet.com/journals/laninf/article>

Freedman DO, Wilder-Smith A. In-flight transmission of SARS-CoV-2: a review of the attack rates and available data on the efficacy of face masks. *Journal of Travel Medicine* 27(8) December 2020. <https://doi.org/10.1093/jtm/taaa178>

Frias JA, ISCIII Clinical Research Network (SCREN); Accessed on line (translated from Spanish) from: <https://www.isciii.es/Noticias/Noticias/Paginas/Noticias/Presentaci%3f%b3n-resultados-preliminares-CombivacS.aspx>



Gallais F, Gantner P, Bruel T, et al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection medRxiv [Preprint] [Posted 2021, May 15] doi: <https://doi.org/10.1101/2021.05.07.21256823>

Goel V, Bulirb D, De Popesita E, et al. COVID-19 International Border Surveillance Cohort Study at Toronto's Pearson Airport medRxiv [Preprint]. [Posted 2021, Mar 1] doi: <https://doi.org/10.1101/2021.02.25.21252404>

Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. *Lancet Public Health* 2021 Published Online April 12, 2021 [https://doi.org/10.1016/S2468-2667\(21\)00055-4](https://doi.org/10.1016/S2468-2667(21)00055-4). Available from: <https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900055-4>

Grandjean D, Marzooqi DHA, Lecoq-Julien C, et al. Use Of Canine Olfactory Detection For COVID-19 Testing Study On U.A.E. Trained Detection Dog Sensitivity. medRxiv [Pre-print] [2021, Jan 20] doi: <https://doi.org/10.1101/2021.01.20.427105>

Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *N Engl J Med* April 9, 2021. DOI: 10.1056/NEJMoa2104840. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2104840>

Groß R, Zanon M, Seidela A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv [preprint] [Posted 2021, June 1]. doi: <https://doi.org/10.1101/2021.05.30.21257971>

Gruskay JA, Dvorzhinskiy A, Konaris MA. Universal Testing for COVID-19 in Essential Orthopaedic Surgery Reveals a High Percentage of Asymptomatic Infections, *The Journal of Bone and Joint Surgery*: August 19, 2020 - Volume 102 - Issue 16 - p 1379-1388 doi: 10.2106/JBJS.20.01053. Available from: [https://journals.lww.com/jbjsjournal/Fulltext/2020/08190/Universal\\_Testing\\_for\\_COVID\\_19\\_in\\_Essential.1.aspx](https://journals.lww.com/jbjsjournal/Fulltext/2020/08190/Universal_Testing_for_COVID_19_in_Essential.1.aspx)

Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Published Online May 5, 2021 [https://doi.org/10.1016/S0140-6736\(21\)00947-8](https://doi.org/10.1016/S0140-6736(21)00947-8)

Hadei M, Moheddi SR, Hopke PK, et al. Presence of SARS-CoV-2 in the air of public places and transportation. *Atmospheric Pollution Research* 2021 Mar. 12(3): 302-306 Available from: <https://www.sciencedirect.com/science/article/pii/S1309104220303585>

Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020 medRxiv [Pre-print] [2021, Jan 15]. doi: <https://doi.org/10.1101/2021.01.13.21249642>

Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. 2021 Mar. *Lancet* DOI: [https://doi.org/10/1016/S0140-6736\(21\)00575-4](https://doi.org/10/1016/S0140-6736(21)00575-4)

Harris RJ, Hall JA, Zaidi A, et al. Impact of vaccination on household transmission of SARS-COV-2 in England. 2021 [On-line – Accessed 29 Apr 2021] Public Health England. Available from: <https://www.gov.uk/government/news/one-dose-of-covid-19-vaccine-can-cut-household-transmission-by-up-to-half>

Harvard APHI (2020). Assessment of Risks of SARS-CoV-2 Transmission During Air Travel and Non-Pharmaceutical Interventions to Reduce Risk Phase One Report: Gate-to-Gate Travel Onboard Aircraft. <https://cdn1.sph.harvard.edu/wp-content/uploads/sites/2443/2020/10/HSPHAPHI-Phase-I-Report.pdf>.



Harvard APHI (2020). Assessment of Risks of SARS-CoV-2 Transmission During Air Travel and Non-Pharmaceutical Interventions to Reduce Risk Phase Two Report: Curb-to-curb travel through airports. <https://cdn1.sph.harvard.edu/wp-content/uploads/sites/2443/2021/02/Harvard-APHI-Phase-Two-Report.pdf>

Hertzberg VS, Weiss H. On the 2-Row Rule for Infectious Disease Transmission on Aircraft. *Ann Glob Health*. 2016 Sep-Oct;82(5):819-823. doi: 10.1016/j.aogh.2016.06.003. PMID: 28283135; PMCID: PMC7104167. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104167/>

Ho D, Wang P, Liu L, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. *Res Sq*. Preprint published online January 29, 2021. Available from doi: [10.21203/rs.3.rs-155394/v1](https://doi.org/10.21203/rs.3.rs-155394/v1)

Hoehl S, Karaca O, Kohmer N, Westhaus S, Graf J, Goetsch U, Ciesek S. Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group. *JAMA Netw Open*. 2020 Aug 3;3(8):e2018044. doi: 10.1001/jamanetworkopen.2020.18044. PMID: 32809029; PMCID: PMC7435338. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2769383>

Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild MJGT, Kann G, Wolf T, Gottschalk R, Ciesek S. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. *N Engl J Med*. 2020 Mar 26;382(13):1278-1280. doi: 10.1056/NEJMc2001899. Epub 2020 Feb 18. PMID: 32069388; PMCID: PMC7121749. Available from: <https://www.nejm.org/doi/full/10.1056/nejmc2001899>

Hoffman M, Hofmann-Winkler H, Krüger N, et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades 2 antibodies induced by infection and vaccination bioRxiv [Preprint] [Posted 2021, May 5]. doi: <https://doi.org/10.1101/2021.05.04.442663>

Holmdahl I, Kahn R, Hay JA, et al. Estimation of Transmission of COVID-19 in Simulated Nursing Homes With Frequent Testing and Immunity-Based Staffing. *JAMA Netw Open*. 2021; 4(5):e2110071. [Accessed May 14, 2021] Doi: 10.1001/jamanetworkopen.2021.10071. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779870>

Horby P, Huntley C, Davies N, et al. Paper from the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) on new coronavirus (COVID-19) variant B.1.1.7. Posted January 21, 2021. Accessed April 14, 2021. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/955239/NERVTAG\\_paper\\_on\\_variant\\_of\\_concern\\_VOC\\_B.1.1.7.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/955239/NERVTAG_paper_on_variant_of_concern_VOC_B.1.1.7.pdf)

Hu M, Lin H, Wang J, Xu C, Tatem AJ, Meng B, Zhang X, Liu Y, Wang P, Wu G, Xie H, Lai S. The risk of COVID-19 transmission in train passengers: an epidemiological and modelling study. *Clin Infect Dis*. 2020 Jul 29;ciaa1057. doi: 10.1093/cid/ciaa1057. Epub ahead of print. PMID: 32726405; PMCID: PMC7454391. Available from: <https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa1057/5877944>

Humphries RM, Azar MM, Calienda AM, et al. To test, perchance to diagnose: practical strategies for severe acute respiratory syndrome coronavirus 2 testing. *Open Forum Inf Dis* 8(4), Apr 2021, ofab095. <https://doi.org/10.1093/ofid/ofab095>

Ikegame S, Siddiquey MNA, Hung C, et al. Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants. *MedRxiv* [Preprint]. [Posted 2021 Apr 3]. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.31.21254660v2>



International Civil Aviation Organisation. Guidance for Air Travel through the COVID-19 Public Health Crisis. Available from: <https://www.icao.int/covid/cart/Pages/CART-Take-off.aspx>

James A, Eagle L, Phillips C, et al. High COVID-19 attack rate among attendees at events at a church — Arkansas, March 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:632-635. Korea. *Emerg Infect Dis.* 2020;26:1917-1920. Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6920e2.htm>

Jang S, Han SH, Rhee JY. Cluster of coronavirus disease associated with fitness dance classes, South Korea. *Emerg Infect Dis.* 2020;26:1917-1920. Available from: [https://wwwnc.cdc.gov/eid/article/26/8/20-0633\\_article](https://wwwnc.cdc.gov/eid/article/26/8/20-0633_article)

Johansson MA, Wolford H, Paul P, et al. Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing. *BMC Medicine* [On line, 2021 Apr 21] Available from: <https://www.medrxiv.org/content/10.1101/2020.11.23.20237412v1>

Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Netw Open.* 2021;4(1):e2035057. doi:10.1001/jamanetworkopen.2020.35057 Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2774707>

Jones NK, Rivett L, Seaman S, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. *Epidemiol Global Health Microbiol Infect Dis: eLife* 2021;10:e68808 DOI: [10.7554/eLife.68808](https://doi.org/10.7554/eLife.68808)

Karron RA, Key NS, Sharfstein JM. Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. *JAMA.* Published online April 30, 2021. doi:10.1001/jama.2021.7637 Available from: <https://jamanetwork.com/journals/jama/fullarticle/2779732>

Kateralis AL, Wells J, Clark P, et al. Epidemiologic Evidence for Airborne Transmission of SARS-CoV-2 during Church Singing, Australia, 2020. *Emerg inf Dis* 27(6) June 2021. Available from: [https://wwwnc.cdc.gov/eid/article/27/6/21-0465\\_article](https://wwwnc.cdc.gov/eid/article/27/6/21-0465_article)

Keehner J, Horton L, Pfeffer MA, et al. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. *N Engl J Med.* 2021 Mar. Available from: [https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=featured\\_home](https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=featured_home)

Khanh NC, Thai PQ, Quach H et al. In-flight transmission of SARS-CoV-2 during a long-haul flight: results from an outbreak investigation in Vietnam and implications for future air travel. *Emerg Infect Dis Online.* Available from: [https://wwwnc.cdc.gov/eid/article/26/11/20-3299\\_article](https://wwwnc.cdc.gov/eid/article/26/11/20-3299_article)

Khatib AN, Carvalho A, Primavesi R, et al. Navigating the Risks of Flying During COVID-19: A Review for Safe Air Travel. *Travel Med* 2020 Dec 23;27(8):taaa212. doi: 10.1093/jtm/taaa212. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717328/pdf/taaa212.pdf>

Kiang MV, Chin ET, Huynh BQ, et al. Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study. *Lancet Infectious Diseases* (March 22, 2021). Available from DOI: [https://doi.org/10.1016/S1473-3099\(21\)00134-1](https://doi.org/10.1016/S1473-3099(21)00134-1)

Kinahan SM, Silcott DB, Silcott BE, et al. Aerosol tracer testing in Boeing 767 and 777 aircraft to simulate exposure potential of infectious aerosol such as SARS-CoV-2. *medRxiv* [Pre-Print] [Posted 2020, Jan 13]. Available from DOI: <https://doi.org/10.1101/2021.01.11.21249626>

Kissler SM, Fauver JR, Mack C, et al. Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. *medRxiv* [Pre-print] [Posted 2021, Feb 21] doi: <https://doi.org/10.1101/2021.02.16.21251535>



Klompas M, Baker MA, Rhee C. Airborne transmission of SARS-CoV-2: theoretical considerations and available evidence. *JAMA*. 2020;324:441-442. Available from:

<https://jamanetwork.com/journals/jama/fullarticle/2768396>

Krutikov M, Palmer T, Tut G, et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. *Lancet Healthy Longev* 2021; 2: e362–70. Available from: [https://doi.org/10.1016/S2666-7568\(21\)00093-3](https://doi.org/10.1016/S2666-7568(21)00093-3)

Kustin T, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals 2021 Apr. Preprint. Available from: Available from DOI: <https://doi.org/10.1101/2021.04.06.21254882>

Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R. Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. *medRxiv* [Preprint]. 2020 Sep 8. Available from: <https://www.medrxiv.org/content/10.1101/2020.06.22.20136309v2>.

Lash RR, Moonan PK, Byers BL, et al. COVID-19 Case Investigation and Contact Tracing in the US, 2020. *JAMA Netw Open*. 2021;4(6):e2115850. doi:10.1001/jamanetworkopen.2021.15850. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780568>

Letizia AG, Ramos I, Obla A, et al. SARS-CoV-2 transmission among marine recruits during quarantine. *N Engl J Med* 2020; 383:2407-2416. DOI: 10.1056/NEJMoa2029717. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2029717>

Levine-Tiefenbrun, M., Yelin, I., Katz, R. et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med* (2021). <https://doi.org/10.1038/s41591-021-01316-7>

Lillie PJ, O'Brien PJ, Lawtie M, et al. First dose of BNT162b2 mRNA vaccine in a Health Care Worker cohort is associated with reduced symptomatic and asymptomatic SARS-CoV-2 infection, *Clinical Infectious Diseases*, 2021;, ciab351, <https://doi.org/10.1093/cid/ciab351>

Lipsitch M, Kahn R. Interpreting vaccine efficacy trial results for infection and transmission. *medRxiv* [Preprint] [Posted 2021, Feb 28] doi: <https://doi.org/10.1101/2021.02.25.21252415>

Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. *N Engl J Med* Pre-print, 2021 Mar. DOI: 10.1056/NEJMc2102017. Available from: [https://www.nejm.org/doi/full/10.1056/NEJMc2102017?query=featured\\_home](https://www.nejm.org/doi/full/10.1056/NEJMc2102017?query=featured_home)

Liu Y, Liu J, Xia H, et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. *N Engl J Med* Pre-print, 2021 May. DOI: 10.1056/NEJMc2106083. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2106083?query=TOC>

Lu J, Gu J, Li K, Xu C, Su W, Lai Z, Zhou D, Yu C, Xu B, Yang Z. COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. *Emerg Infect Dis*. 2020 Jul;26(7):1628-1631. doi: 10.3201/eid2607.200764. Epub 2020 Apr 2. PMID: 32240078; PMCID: PMC7323555. Available from: [https://wwwnc.cdc.gov/eid/article/26/7/20-0764\\_article](https://wwwnc.cdc.gov/eid/article/26/7/20-0764_article)

Lumley SF, Rodger G, Constantinides B, et al. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. *medRxiv*. 2021:2021.03.09.21253218. [Pre-print] [Posted 2021, Mar 12]. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.09.21253218v1>



McEllistrem MC, Clancy CJ, Buehrle DJ, et al. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19. *Clin Infect Dis*. 2021 Mar 26:ciab263. doi: 10.1093/cid/ciab263. Epub ahead of print. PMID: 33768222; PMCID: PMC8083695. Available from: <https://pubmed.ncbi.nlm.nih.gov/33768222/>

Mades A, Chellamathu P, Lopez L, et al. Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and 2 upper respiratory tract specimens following COVID-19 mRNA vaccination. medRxiv [Pre-print] [Posted 2021, May 7]. Available from: <https://www.medrxiv.org/content/10.1101/2021.05.06.21256403v1.full.pdf>

Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* [Pre-print] 2021 Mar. DOI: 10.1056/NEJMoa2102214. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2102214?query=TOC>

Mallapaty S. How many COVID deaths are acceptable in a post-pandemic world? *Nature* 593, 326-327 (2021) doi: <https://doi.org/10.1038/d41586-021-01220-7>

Marc A, Kerioui M, Blanquart F. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. medRxiv [Preprint] [Posted 2021, May 8] doi: <https://doi.org/10.1101/2021.05.07.21256341>

Marks M, Millat-Martinez P, Ouchi D. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis* 2021; 21: 629–36 Published Online February 2, 2021 [https://doi.org/10.1016/S1473-3099\(20\)30985-3](https://doi.org/10.1016/S1473-3099(20)30985-3). Available from: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30985-3/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30985-3/fulltext)

Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 Viral Variants—Tackling a Moving Target. *JAMA*. 2021;325(13):1261–1262. doi: 10.1001/jama.2021.2088 Available from: <https://jamanetwork.com/journals/jama/fullarticle/2776542>

Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *The Lancet Infectious Diseases* Published Online April 27, 2021 [https://doi.org/10.1016/S1473-3099\(21\)00224-3](https://doi.org/10.1016/S1473-3099(21)00224-3). Available from: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00224-3/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00224-3/fulltext)

Mina MJ, Parker R & Larremore DB. Rethinking Covid-19 test sensitivity: a strategy for containment. *N Engl J Med* 383, e120 (2020). Available from: <https://www.nejm.org/doi/full/10.1056/NEJMp2025631>

Milman O, Yelin I, Aharony N, et al. SARS-CoV-2 infection risk among unvaccinated is negatively associated with community-level vaccination rates. medRxiv [Pre-print] [Posted 2021, Mar 31]. Available from: doi: <https://doi.org/10.1101/2021.03.26.21254394>

Mina MJ, Peto TE, Garcia-Finana et al. Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. *Lancet* [Pre-print] 2021 Feb. DOI: [https://doi.org/10.1016/S0140-6736\(21\)00425-6](https://doi.org/10.1016/S0140-6736(21)00425-6)

Monge S, Olmedo C, Alejos B, et al. Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain. medRxiv [Pre-print] [Posted 2021, Apr 15]. doi: <https://doi.org/10.1101/2021.04.08.21255055>

Moustsen-Helms IR, Emborg H, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study. medRxiv [Preprint] [Posted 2021, Mar 9]. doi: <https://doi.org/10.1101/2021.03.08.21252200>



Muhi S, Tayler N, Hoang T, et al. Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study. *Lancet Regional Health* [Pre-print] [Published 2021, Mar 2]. DOI: <https://doi.org/10.1016/j.lanwpc.2021.100115>

Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination, *Clinical Infectious Diseases*, 2021;, ciab381, <https://doi.org/10.1093/cid/ciab381>

Munitz A, Yechezkel M, Dickstein Y, et al. BNT162b2 Vaccination Effectively Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in high risk populations in Israel. *Cell Reports Medicine* (2021), doi: <https://doi.org/10.1016/j.xcrm.2021.100264>.

Murphy N, Boland M, Bambury N, et al. A large national outbreak of COVID-19 linked to air travel, Ireland, summer 2020. *Euro Surveill* 2020;25:2001624. PMID:33094715 <https://doi.org/10.2807/1560-7917.ES.2020.25.42.2001624>

Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. *JAMA Netw Open*. 2021;4(5):e2111417. doi:10.1001/jamanetworkopen.2021.11417. Available from: [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780376?utm\\_source=For\\_The\\_Media&utm\\_medium=referral&utm\\_campaign=ftm\\_links&utm\\_term=052621](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780376?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052621)

Nir-Paz R, Grotto I, Strolov I, Salmon A, Mandelboim M, Mendelson E, Regev-Yochay G. Absence of in-flight transmission of SARS-CoV-2 likely due to use of face masks on board. *J Travel Med*. 2020 Jul 14:taaa117. doi: 10.1093/jtm/taaa117. Epub ahead of print. PMID: 32662832; PMCID: PMC7454758. Available from: <https://academic.oup.com/jtm/advance-article/doi/10.1093/jtm/taaa117/5871227>

Nkemakonam CO, Barker AP, Curtis K, et al. Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting. *Journal of Clinical Microbiology* Mar 2021, 59 (4) e03282-20; DOI: 10.1128/JCM.03282-20. Available from: <https://jcm.asm.org/content/59/4/e03282-20>

Norizuki M, Hachiya M, Motohashi A, et al. Effective screening strategies for detection of asymptomatic COVID-19 travelers at airport quarantine stations: Exploratory findings in Japan. *Global Health Med* [Advance Publication] DOI: 10.35772/ghm.2020.01109. Available from: [https://www.jstage.jst.go.jp/article/ghm/advpub/0/advpub\\_2020.01109/article](https://www.jstage.jst.go.jp/article/ghm/advpub/0/advpub_2020.01109/article)

O'Connell J, O'Keefe DT. Contact Tracing for Covid-19 — A Digital Inoculation against Future Pandemics. *N Engl J Med* [2021, May 19] DOI: 10.1056/NEJMp2102256. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMp2102256?query=TOC>

Oh S, Jeong H, Chang E, et al. *J Korean Med Sci*. 2021 Apr 12;36(14):e101. Published online Apr 01, 2021. <https://doi.org/10.3346/jkms.2021.36.e101>

Olsen SJ, Chang HL, Cheung TY, Tang AF, Fisk TL, Ooi SP, Kuo HW, Jiang DD, Chen KT, Lando J, Hsu KH, Chen TJ, Dowell SF. Transmission of the severe acute respiratory syndrome on aircraft. *N Engl J Med*. 2003 Dec 18;349(25):2416-22. doi: 10.1056/NEJMoa031349. PMID: 14681507. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa031349>

Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. *Ann Int Med*. 2021 Jan. Available from: <https://www.acpjournals.org/doi/10.7326/M20-6976>

Osmanodja B, Budde K, Zickler D, et al. Diagnostic accuracy of a novel SARS-CoV-2 antigen-detecting rapid diagnostic test from standardized self-collected anterior nasal swabs. *medRxiv* [Pre-print] [Posted 2021, Apr 23] <https://www.medrxiv.org/content/10.1101/2021.04.20.21255797v1.full.pdf>



Oxera and Edge Health (Nov 2020), 'Modelling the effectiveness of airport testing regimes' Report prepared for Virgin Atlantic, IAG, TUI, Heathrow, MAG, Collinson, Airlines UK and IATA

Available from: <https://www.oxera.com/wp-content/uploads/2020/11/Modelling-the-effectiveness-of-airport-testing-regimes-061120.pdf>

Oxera and Edge Health (Mar 2021), 'Assessment of the effectiveness of rapid testing for SARS-Cov-2'. Impact of vaccination on risk of international air travel. Report prepared for IATA.

Available from: <https://www.oxera.com/wp-content/uploads/2021/03/Assessment-of-the-effectiveness-of-rapid-tests.pdf>

Oxera and Edge Health (Mar 2021), 'Effectiveness of dual-testing schemes for air passengers' Report prepared for Virgin Atlantic, IAG, Heathrow, MAG, and IATA. Available from: <https://www.oxera.com/wp-content/uploads/2021/03/Effectiveness-of-dual-testing-schemes-for-air-passengers.pdf>

Oxera and Edge Health (Mar 2021), ' Report prepared for Manchester Airports Group. Available from: <https://www.oxera.com/about-us/media-centre/travel-corridor-list-could-be-more-than-doubled-with-no-increase-in-risk-due-to-uk-vaccination-programme/>

Oxera and Edge Health (Apr 2021), 'Effectiveness of testing for COVID-19: evidence from airline trials at Heathrow Airport'. Report prepared for Heathrow Airport Limited. Available from: <https://www.oxera.com/wp-content/uploads/2021/04/airline-trials-at-Heathrow.pdf>

Pana TA, Bhattacharya S, Gamble DT, *et al.* Country-level determinants of the severity of the first global wave of the COVID-19 pandemic: an ecological study. *BMJ Open* 2021;**11**:e042034. doi: 10.1136/bmjopen-2020-042034. Available from: <https://bmjopen.bmj.com/content/11/2/e042034#F1>

Pang JK, Jones SP, Waite LL, *et al.* Probability and Estimated Risk of SARS-CoV-2 Transmission in the Air Travel System: A Systemic Review and Meta-Analysis. *medRxiv* [Pre-print] [Posted 2021, Apr 14]. Available from: <https://doi.org/10.1101/2021.04.08.21255171>

Pavli A, Smeti P, Hadjianastasiou S, Theodoridou K, Spilioti A, Papadima K, Andreopoulou A, Gkolfinopoulou K, Sapounas S, Spanakis N, Tsakris A, Maltezou HC. In-flight transmission of COVID-19 on flights to Greece: An epidemiological analysis. *Travel Med Infect Dis.* 2020 Sep 17;38:101882. doi: 10.1016/j.tmaid.2020.101882. Epub ahead of print. PMID: 32949700; PMCID: PMC7494513. Available from: <https://doi.org/10.1016/j.tmaid.2020.101882>

Pawlowski C, Lenehan P, Puranik A, *et al.* FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. *medRxiv* (Preprint, February 18, 2021). Available from: <https://www.medrxiv.org/content/10.1101/2021.02.15.21251623v3>

Pegu A, O'Connell S, Schmidt SD, *et al.* Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. *bioRxiv* [Pre-print] [Posted 2021, May 16]. doi: <https://doi.org/10.1101/2021.05.13.444010>

Pekosz A, Parvu V, Li M, *et al.* Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. 2021 Jan. *Clinical Infectious Diseases*, ciaa1706, <https://doi.org/10.1093/cid/ciaa1706>



Pilarowski G, Marquez C, Rubio L et al. Field performance and public health response using the BinaxNOW™ Rapid SARS-CoV-2 antigen detection assay during community-based testing. 2020 Dec. *Clinical Infectious Diseases*, ciaa1890, available from: <https://doi.org/10.1093/cid/ciaa1890>

Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel – 33 US sites, January-March 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:753-758. DOI: <http://dx.doi.org/10.15585/mmwr.mm7020e2>external icon. Available from: [https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e2.htm?s\\_cid=mm7020e2\\_w](https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e2.htm?s_cid=mm7020e2_w)

Piri SM, Edalatfar M, Shool S, et al. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. *Infectious Diseases (London, England)*, 28 Jan 2021, 53(5):315-324 Available from: DOI: [10.1080/23744235.2020.1871066](https://doi.org/10.1080/23744235.2020.1871066)

Pollock NR, Jacobs JR, Tran K, et al. Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts. *Journal of Clinical Microbiology* Apr 2021, 59 (5) e00083-21; DOI: 10.1128/JCM.00083-21. Available from: <https://jcm.asm.org/content/59/5/e00083-21>

Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey. *medRxiv [Pre-print]* [Posted 2021, Apr 23]. doi: <https://doi.org/10.1101/2021.04.22.21255913>

Quilty BJ, Clifford S, Flasche S, Eggo RM, CMMID nCoV working group. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). *Euro Surveill [Internet]*. 2020 Feb;25(5). Available from: <http://dx.doi.org/10.2807/1560->

Quilty BJ, Clifford S, Helliwell J, et al. Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study. *Lancet Public Health* 2021. Published Online January 20, 2021. [https://doi.org/10.1016/S2468-2667\(20\)30308-X](https://doi.org/10.1016/S2468-2667(20)30308-X). Available from: [https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(20\)30263-2/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30263-2/fulltext)

Qureshi A, Baskett WI, Huang W, et al. Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing, *Clinical Infectious Diseases*, 2021;, ciab345, <https://doi.org/10.1093/cid/ciab345>

Rasmussen AL, Popescu SV. Symptomless transmission silently drives viral spread and is key to ending the pandemic. *Science [Mar 2021]* Vol. 371, Issue 6535, pp. 1206-1207. DOI: 10.1126/science.abf9569 Available from: <https://science.sciencemag.org/content/371/6535/1206.full>

Redd AD, Narden A, Kared H. CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. 2021 Mar. *Open Forum Infectious Diseases*, ofab143, <https://doi.org/10.1093/ofid/ofab143>

Ren R, Zhang Y, Li Q, et al. Asymptomatic SARS-CoV-2 infections among persons entering China from April 16 to October 16, 2020. *JAMA*. 2021;325(5):489-492. doi:10.1001/jama.2020.23942 Available from: <https://jamanetwork.com/journals/jama/fullarticle/2775705>

Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing transmission: ending the pandemic with SARS-CoV-2 vaccination. *Open Forum Infectious Diseases*. 2021 May 19. ofab259. <https://doi.org/10.1093/ofid/ofab259>

Rivera-Rios JC, et al. In-flight particulate matter concentrations in commercial flights are likely lower than other indoor environments. 2021. *Indoor Air*, Available from: <https://doi.org/10.1111/ina.12812>



Rossman H, Shilo S, Meir T, et al. COVID-19 dynamics after a national immunization program in Israel. *Nature Med* (2021). <https://doi.org/10.1038/s41591-021-01337-2>

Rubin R. COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough. *JAMA*. 2021;325(13):1241–1243. doi:10.1001/jama.2021.3370. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2777785>

Ruszkiewicz DM, Sanders D, O'Brien R, et al. Diagnosis of COVID-19 by analysis of breath with gas chromatography-ion mobility spectrometry - a feasibility study. *Dec 2020. EClinical Medicine* 29:100609. DOI: <https://doi.org/10.1016/j.eclinm.2020.100609>

Russell TW, Wu JT, Clifford S. Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study. *Lancet Public Health* 2020 Jan. 6(1): E12-E20. Available from: [https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(20\)30263-2/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30263-2/fulltext)

Sadoff J, Davis K, Douoguih M. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer. 2021 Apr 16 [Letter]. *JAMA*. DOI: 10.1056/NEJMc2106075. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2106075?query=TOC>

Sadoff J, Grey G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. April 21, 2021. DOI: 10.1056/NEJMoa2101544. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2101544>

Salo J, Hägg M, Kortelainen M. The indirect effect of mRNA-based Covid-19 vaccination on unvaccinated household members. *medRxiv [preprint] [Posted 2021, May 27]*. doi: <https://doi.org/10.1101/2021.05.27.21257896>

Schultz JB, Berlit P, Diener C, et al. COVID-19 vaccine-associated cerebral venous thrombosis in Germany: a descriptive study. *medRxiv [Pre-print] [Posted 2021, May 4]*. Available from: doi: <https://doi.org/10.1101/2021.04.30.21256383>

Schultz NH, Sorvoli IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* June 3, 2021 *N Engl J Med* 2021; 384:2124-2130. DOI: 10.1056/NEJMoa2104882. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2104882>

Schwartz KL, Murti M, Finkelstein M, Leis JA, Fitzgerald-Husek A, Bourns L, Meghani H, Saunders A, Allen V, Yaffe B. Lack of COVID-19 transmission on an international flight. *CMAJ*. 2020 Apr 14;192(15):E410. doi: 10.1503/cmaj.75015. PMID: 32392504; PMCID: PMC7162437. Available from: <https://www.cmaj.ca/content/cmaj/192/15/E410.full.pdf>

See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. *JAMA*. Published online April 30, 2021. doi:10.1001/jama.2021.7517. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2779731>

Shah ASV, Gribben C, Bishop J, et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. *medRxiv [Preprint] [Posted 2021, Mar 21]*. Available from doi: <https://doi.org/10.1101/2021.03.11.21253275>

Shen Y, Li C, Dong H, et al. Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern China. 2020 Sep. *AMA Intern Med* 180(12):1665-1671. doi:10.1001/jamainternmed.2020.5225. Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770172>

Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. *N Engl J Med [Pre-print]*. 2021, Apr 5. DOI: 10.1056/NEJMoa2103055. Available from:



<https://www.nejm.org/doi/full/10.1056/NEJMoa2103055?query=TOC>

Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARSCoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study) medRxiv [Preprint][Posted 2021, Mar 28] doi: <https://doi.org/10.1101/2021.03.26.2125439>

Smith BJ, Morris AJ, Johnston B, et al. Estimating the effect of selective border relaxation on COVID-19 in New Zealand. 2021 Feb. NZ Med J 134:1529. Available from: <https://www.nzma.org.nz/journal-articles/estimating-the-effect-of-selective-border-relaxation-on-covid-19-in-new-zealand>

Speake H, Phillips A, Chong T, Sikazwe C, Levy A, Lang J, et al. Flight-associated transmission of severe acute respiratory syndrome coronavirus 2 corroborated by whole-genome sequencing. Emerg Infect Dis. 2020 Dec. Available from: [https://wwwnc.cdc.gov/eid/article/26/12/20-3910\\_article](https://wwwnc.cdc.gov/eid/article/26/12/20-3910_article)

Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Science Translational Med. [Published on line, 20 Jan 2021]. Available from: <https://stm.sciencemag.org/content/13/577/eabd2223>

Steyn N, Plank MJ, James A, et al. Royal Society. Managing the risk of a COVID-19 outbreak from border arrivals J. R. Soc. Interface 18: 20210063. <https://doi.org/10.1098/rsif.2021.0063>

Swadi T, Geoghegan J, Devine T, et al. A case study of extended in-flight transmission of SARS-CoV-2 en route to Aotearoa New Zealand. Institute of Environmental Science and Research. 2020 Dec. Preprint. <https://doi.org/10.26091/ESRNZ.13257914.v1>

Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel, Clinical Infectious Diseases, 2021; ciab361, <https://doi.org/10.1093/cid/ciab361>

Tada T, Zhoua H, Dcosta BM, et al. The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. bioRxiv [Preprint] [Posted 2021, May 16] doi: <https://doi.org/10.1101/2021.05.14.444076>

Takuva S, Takalani A, Garrett N, et al. Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. N Engl J Med [on-line]. June 2, 2021. DOI: 10.1056/NEJMc2107920. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2107920>

Tan SH, Allicock O, Armstrong-Hough M, et al. Saliva as a gold-standard sample for SARS-CoV-2 detection. Lancet Respir Med 2021. Published Online April 19, 2021. [https://doi.org/10.1016/S2213-2600\(21\)00178-8](https://doi.org/10.1016/S2213-2600(21)00178-8) Available from: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(21\)00178-8/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00178-8/fulltext)

Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening Clinical Infectious Diseases, ciab229, <https://doi.org/10.1093/cid/ciab229>

Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA Research Letter [On-line] May 6, 2021 <https://jamanetwork.com/journals/jama/fullarticle/2779854>

Tarke A, Sidney J, Methot T, et al. Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccines. bioRxiv [Pre-print] [Posted 2021, Feb 27] doi: <https://doi.org/10.1101/2021.02.27.433180>



Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv [Preprint] [2020 Dec 22]. Available at <https://doi.org/10.1101/2020.12.21.20248640>

Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged  $\geq 65$  Years – United States, January–March 2021. MMWR Morb Mortal Wkly Rep. ePub: 20 April 2021. DOI: [https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e1.htm?s\\_cid=mm7018e1\\_w](https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e1.htm?s_cid=mm7018e1_w)

Thompson HA, Imai N, Dieghe E, et al. SARS-CoV-2 infection prevalence on repatriation flights from Wuhan City, China. J Travel Med 2020 doi: [10.1093/jtm/taaa135](https://doi.org/10.1093/jtm/taaa135)

Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. Available from: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm>

Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study (2021). The Lancet Infectious Diseases 21(1):52-58  
ISSN 1473-3099. [https://doi.org/10.1016/S1473-3099\(20\)30764-7](https://doi.org/10.1016/S1473-3099(20)30764-7)

U.S. National Research Council Committee on Air Quality in Passenger Cabins of Commercial Aircraft. The Airliner Cabin Environment and the Health of Passengers and Crew. Washington (DC): National Academies Press (US); 2002. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK207485/> doi: 10.17226/10238

Vahidy FS, Pischel L, Tano ME, et al. Real World Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the United States. medRxiv [Pre-print] [Posted 2021, Apr. 23]. doi: <https://doi.org/10.1101/2021.04.21.21255873>

Vaidyanathan G. Coronavirus variants are spreading in India – what scientists know so far. Nature 593, 321-322 (2021) doi: <https://doi.org/10.1038/d41586-021-01274-7>

Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021; 397: 1646–57  
Published Online April 23, 2021 [https://doi.org/10.1016/S0140-6736\(21\)00677-2](https://doi.org/10.1016/S0140-6736(21)00677-2). Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00677-2/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00677-2/fulltext)

Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. JAMA Intern Med. Published online May 28, 2021.  
doi:10.1001/jamainternmed.2021.2959. Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2780557>

Wall E, Wu M, Harvey R. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination Lancet [Correspondence] Published Online June 3, 2021 [https://doi.org/10.1016/S0140-6736\(21\)01290-3](https://doi.org/10.1016/S0140-6736(21)01290-3). Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)01290-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext)

Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature (2021). <https://doi.org/10.1038/s41586-021-03398-2>

Wang Z, Galea E, Grandison A, et al. Inflight transmission of COVID-19 based on experimental aerosol dispersion data. J Travel Med teeb023 (Pre-print), available at: <https://doi.org/10.1093/jtm/taab023>

Weekes M, Jones NK, Rivett L, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Authorea. February 24, 2021. doi: [10.22541/au.161420511.12987747/v1](https://doi.org/10.22541/au.161420511.12987747/v1)



- Wei J, Stoeeser N, Matthews PC, et al. The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom. medRxiv [Pre-print] [Posted 2021, Apr 23]. doi: <https://doi.org/10.1101/2021.04.22.21255911>.
- Wells CR, Townsend JP, Pandey A, et al. Optimal COVID-19 quarantine and testing strategies. Nat Commun 12, 356 (2021). <https://doi.org/10.1038/s41467-020-20742-8>
- White EM, Blackman C, Feifer RA, et al. Incident SARS-CoV-2 infection among nRNA-vaccinated and unvaccinated nursing home residents. N Engl J Med [Letter] [2021, May 19]. DOI: 10.1056/NEJMc2104849 Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2104849?query=TOC>
- Wilder-Smith A, Leong HN, Villacian JS. In-flight transmission of Severe Acute Respiratory Syndrome (SARS): a case report. J Travel Med. 2003;10(5):299-300. <https://doi.org/10.2310/7060.2003.2737> PMID: 14531986 Available from: <https://www.deepdyve.com/lp/oxford-university-press/a-case-of-in-flight-transmission-of-severe-acute-respiratory-syndrome-6Y6HMDp3WA>
- Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv [Pre-print] [2021, Jan 25]. doi: <https://doi.org/10.1101/2021.01.25.427948>
- Wu K, Choi A, Koch M, et al. Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster. medRxiv [Pre-print] [2021, May 6]. doi: <https://doi.org/10.1101/2021.05.05.21256716>
- Wyllie A, Fournier J, Cassanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med 2020; 383:1283-1286 DOI: 10.1056/NEJMc2016359. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2016359>
- Yang HS, Costa V, Racine-Brzostek SE, et al. Association of age with SARS-CoV-2 antibody response. JAMA Netw Open. 2021;4(3):e214302. doi:10.1001/jamanetworkopen.2021.4302. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743>
- Yang N, Shen Y, Shi C, Ma AHY, Zhang X, Jian X, Wang L, Shi J, Wu C, Li G, Fu Y, Wang K, Lu M, Qian G. In-flight Transmission Cluster of COVID-19: A Retrospective Case. MedRxiv [Preprint]. [Posted 2020 Mar 30]. Available from: <https://www.medrxiv.org/content/10.1101/2020.03.28.20040097v1.full.pdf>
- Yang Q, Saldi TK, Lasda E, et al. Just 2% of SARS-CoV-2 positive individuals carry 90% of the virus circulating in communities. medRxiv [Preprint]. 2021 Mar 5. DOI: <https://www.medrxiv.org/content/10.1101/2021.03.01.21252250v1>
- Yokota I, Shane PY, Okada K, et al. A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study. Lancet Microbe 2021 Published Online May 19, 2021 [https://doi.org/10.1016/S2666-5247\(21\)00092-6](https://doi.org/10.1016/S2666-5247(21)00092-6). Available from: [https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(21\)00092-6/fulltext](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00092-6/fulltext)